BostonGene Corporation (BostonGene), a biomedical software company, based upon developing therapeutic precision therapies for cancer patients, has confirmed its partnership with the Weinstock Laboratory, a translation testing center on new treatments for lymphoid-malignant diseases at Dana-Farber Cancer Institute, Inc. This partnership aims to establish predictors for PI3 kinase inhibition in retroactive / refractory T cell lymphomas.

About BostonGene and Its Technology

BostonGene corporation is a leader in using biomedical applications for advanced patient monitoring and customized decision-making in the area of cancer.

An individual, a proprietary technique, was developed by BostonGene to decode tumor microenvironmental properties and compositions from bulk RNA sequencing comparable to traditional approaches. By integrating high-performance sequencing, individual cell and multiplexed tumor imaging data, and clinical information about the disease and the patient, they digitize the tumor’s microenvironment and genetics.

To facilitate scientific decision-making, BostonGene has developed a knowledge and analytics framework for cloud-based research oncology and immunology. The BostonGene cloud platform conducts precision analytics against patient data in terabytes and presents the findings in a well-structured and intuitive format, allowing a tiered view of a custom molecular tumor model.

About Collaboration

• Research efforts in Duvelisib (the PI3 K delta & gamma inhibitor) in T-cella (TLC) patients are led by the Weinstock Laboratory to discover pathways for sensitivity and resistance to and potential cause of adverse effects.

• BostonGene offers advanced analytics in this partnership to predict drug reaction by identifying new biomarkers and genomic, transcriptomic, proteomic and multiplex data sets.

• BostonGene uses a range of unique decoiling algorithms to reveal cellular tumor material and the surrounding microenvironment by using next-generation transcriptome sequencing data (NGS) and imaging analysis algorithms. In this tumor, microenvironment distribution spatial parameters elucidated by the use of imagery data for immunofluorescence (IF).

Potential Impact of This Collaboration

• Improvement of patient outcomes accurately predicts which patients should be treated by discovering new biomarkers for other cancer patients.

• The probability of having significant benefits in care decisions for the physicians.

• RNAseq analysis and exome sequencing may establish the genomics and transcriptional changes that may serve as predictive biomarkers in PI3 kinase reaction and resistance, which may eventually improve patient outcomes.

Potential Impact on Biomedical Industry

Collaboration through the biomedical research and development ecosystem has been crucial for critical scientific developments in new diagnostics technologies and the identification of molecular targets for personalized medicines. Such innovations form drug technology development as it will:

• Enhance research during a formal collaborative process

• Help collaborators achieve more effective and timelier scientific and technical advances and offer patients faster new technologies.

• Increase care and health benefits by the selection of the right population

• Discuss quality and demonstrate a reduction in healthcare costs globally